Marketing: Page 21
-
Third Neulasta biosimilar on its way as Sandoz wins long-delayed FDA approval
Novartis' drug will be third to market, but copycat drugs have already taken a chunk of the market away from Amgen's branded version.
By Jonathan Gardner • Nov. 5, 2019 -
Sponsored by Syneos Health
Five recent developments radically re-shaping new drug commercialization
Emerging companies and drug developers need a new game plan and new resources as their pipelines mature, often choosing to go solo where previous players partnered with others.
By Dominic Marasco, RPh • Nov. 1, 2019 -
Explore the Trendline➔
Brian Tucker / BioPharma Dive/BioPharma Dive
TrendlineCommercialization
New drugs for obesity are becoming blockbusters, while Trump administration pressure is reshaping pharma marketing strategies ahead of looming patent cliffs.
By BioPharma Dive staff -
Sanofi pays $315 million to settle Lemtrada go-slow claims
The administrator of a contingent value right tied to Sanofi's buyout of Genzyme argued the pharma slowed Lemtrada's progress to dodge billions in potential payouts.
By Jonathan Gardner • Oct. 31, 2019 -
FDA panel backs withdrawal of Amag drug to prevent preterm birth
An advisory committee narrowly recommended the FDA rescind approval for Makena, which showed no benefit in a confirmatory study.
By Ned Pagliarulo • Oct. 30, 2019 -
CMS proposes lifting restrictions on next-gen sequencing tests for cancer
The agency revised its proposed national coverage determination after receiving more than 80 comments, with plans to extend coverage of next generation sequencing tests to earlier-stage and hereditary cancers.
By Nick Paul Taylor • Oct. 30, 2019 -
Gilead CAR-T sales slow, renewing growth doubts
Yescarta, the cell therapy Gilead acquired in its $12 billion deal for Kite, appeared to hit a snag, with sales from July to September declining versus the second quarter.
By Ned Pagliarulo • Oct. 25, 2019 -
Vertex clears its biggest commercial hurdle: UK insurance coverage
After months of testy negotiations, Vertex and English health authorities have created a reimbursement plan for the company's cystic fibrosis drugs.
By Jacob Bell • Oct. 24, 2019 -
5 insights from a chat with Larry Merlo, CEO of CVS Health
Healthcare Dive talked to Merlo about competing with Amazon, the path to buying Aetna and new areas in which CVS could play a role.
By Rebecca Pifer Parduhn • Oct. 23, 2019 -
Sponsored by MicroMass
Assessing provider (and patient) motivation
Behavioral science provides a roadmap to understanding how HCPs make decisions and what drives prescribing behavior, but more importantly, it gives us strategies that we can apply to disrupt the status quo.
By Patty Zipfel, PhD, ISMPP, CMPP™ VP, Scientific Strategy MicroMass Communications, Inc. • Oct. 23, 2019 -
Novartis' Zolgensma starts strong as about 100 infants are treated with gene therapy
Sales totaled $160 million in the gene therapy's first full quarter of commercial availability, well above Wall Street's expectations.
By Andrew Dunn • Oct. 22, 2019 -
Vertex wins speedy approval for cystic fibrosis triplet
With Trikafta cleared by the Food and Drug Administration, Vertex estimates its drugs can treat as much as 90% of patients with the lung condition.
By Jacob Bell • Oct. 21, 2019 -
Teva offers $23B of Suboxone to get out of opioid litigation
Whether such a deal would be widely accepted wasn't clear, however, amid reports attorneys for plaintiff municipalities had already rejected Teva's "agreement in principle."
By Jonathan Gardner • Oct. 21, 2019 -
Drug distributors, Teva settle in Ohio opioid case
The companies, which include AmerisourceBergen, McKesson and Cardinal Health, will pay $260 million to two Ohio counties to avoid a trial.
By Jonathan Gardner • Updated Oct. 21, 2019 -
Bristol-Myers, Pfizer partner with Fitbit to speed AFib diagnosis
The two drugmakers market Eliquis, a top-selling anticoagulant approved for stroke prevention in individuals with atrial fibrillation.
By David Lim • Oct. 17, 2019 -
Novartis backs away from marketing Pear digital therapeutics
While Sandoz and Pear are still working together, the Swiss pharma unit will no longer co-promote the recently launched reSET and reSET-O.
By Kristin Jensen • Oct. 16, 2019 -
On second thought, AbbVie's new arthritis drug not so costly, ICER says
A re-evaluation of Rinvoq makes it look like a better value, although the group's estimate says it offers "marginal clinical benefit" compared to Humira.
By Jonathan Gardner • Oct. 11, 2019 -
Parexel partners with Datavant on real-world data
The agreement reflects a growing hunger among drug developers for real-world data and analytics services.
By Kristin Jensen • Oct. 10, 2019 -
Sponsored by StackAdapt
Native ISI rich media: A prescription for the ultimate digital pharma campaign
In a rapidly growing industry, solutions exist that meet the two key criteria of a successful pharmaceutical campaign: visibility and compliance.
Oct. 10, 2019 -
Alex Wong via Getty Images
HHS pitches sweeping revamp of Anti-Kickback Statute, Stark Law
Pharmaceutical companies are excluded from the changes, but HHS head Alex Azar said work is ongoing on separate regulations for the drug industry.
By David Lim • Oct. 9, 2019 -
Elizabeth Regan/BioPharma Dive
With new report, ICER puts itself at center of drug pricing storm
Pharma price hikes added billions of dollars to U.S. spending in 2017 and 2018. For seven top drugs, the watchdog found those increases came with little new clinical evidence in support.
By Ned Pagliarulo • Updated Oct. 8, 2019 -
Eylea casts a shadow over Novartis' latest approval
At least one analyst sees few reasons for doctors to use Novartis' Beovu in place of the Regeneron eye drug, citing a less-than-ideal label.
By Jacob Bell • Oct. 8, 2019 -
Buttigieg targets pharma in aggressive plan to lower drug prices
The presidential hopeful supports several policies, such as direct drug price negotiation, that feature in legislation proposed by House Democrats.
By Ned Pagliarulo • Oct. 7, 2019 -
Gilead's follow-on PrEP drug gets broad label, but with a notable exclusion
The FDA approved Descovy to prevent HIV infection in adults and adolescents, but not for cisgender women.
By Jacob Bell • Oct. 4, 2019 -
Sponsored by Yext
How to relaunch your healthcare website in the new era of search
Patient search behavior has changed. Here's what to expect when relaunching your healthcare website.
Oct. 4, 2019 -
Gene therapy stocks have taken a beating. Their recovery may be slow
Share prices of at least 26 gene therapy biotechs were down on the year in October, a sign of some investor uncertainty on how the drugs will be sold.
By Jacob Bell • Oct. 3, 2019
Previous
